Coldstream Capital Management Inc. Purchases 712 Shares of Humana Inc. (NYSE:HUM)

Coldstream Capital Management Inc. boosted its position in Humana Inc. (NYSE:HUM) by 27.3% during the third quarter, HoldingsChannel reports. The fund owned 3,318 shares of the insurance provider’s stock after buying an additional 712 shares during the quarter. Coldstream Capital Management Inc.’s holdings in Humana were worth $1,032,000 as of its most recent filing with the SEC.

Several other institutional investors have also added to or reduced their stakes in HUM. CarsonAllaria Wealth Management Ltd. raised its position in shares of Humana by 111.4% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after purchasing an additional 39 shares during the period. Creative Financial Designs Inc. ADV grew its stake in Humana by 244.0% in the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock valued at $27,000 after buying an additional 61 shares in the last quarter. Atwood & Palmer Inc. bought a new stake in Humana during the 3rd quarter valued at $29,000. Hantz Financial Services Inc. bought a new stake in Humana during the 2nd quarter valued at $35,000. Finally, Family Firm Inc. purchased a new stake in shares of Humana during the second quarter worth $37,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently issued reports on HUM shares. Leerink Partnrs lowered Humana from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Cantor Fitzgerald reissued a “neutral” rating and issued a $395.00 price target on shares of Humana in a report on Tuesday, October 1st. Jefferies Financial Group cut shares of Humana from a “buy” rating to a “hold” rating and reduced their price objective for the company from $519.00 to $253.00 in a research note on Monday, October 7th. JPMorgan Chase & Co. increased their target price on shares of Humana from $332.00 to $396.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 21st. Finally, Stephens restated an “equal weight” rating and set a $250.00 price target on shares of Humana in a research report on Wednesday, October 9th. Twenty equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, Humana has a consensus rating of “Hold” and an average price target of $304.15.

Humana Price Performance

Shares of NYSE:HUM opened at $272.78 on Friday. The company’s fifty day moving average is $272.83 and its 200 day moving average is $325.59. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. Humana Inc. has a 52 week low of $213.31 and a 52 week high of $488.89. The stock has a market cap of $32.85 billion, a PE ratio of 24.16, a PEG ratio of 2.18 and a beta of 0.53.

Humana (NYSE:HUM) last released its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, beating analysts’ consensus estimates of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The company had revenue of $29.30 billion during the quarter, compared to analyst estimates of $28.66 billion. Research analysts anticipate that Humana Inc. will post 16.14 earnings per share for the current year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.30%. The ex-dividend date of this dividend is Tuesday, December 31st. Humana’s dividend payout ratio is 31.36%.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.